ADRED – Adverse drug reactions (ADR) leading to emergency department (ED) visits: Causality analysis and preventability rate of the ADRs

Conditions

Y57 T88.0

Berres J, Wozniak J, Fölsch H, Knueppel-Ruppert A, Graeff V, Kriegisch-Stumpf A, Dormann H, Stingl JC, Just KS.

2026-02-20

Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study

Katja S. Just, Karen A. Schultze, Harald Dormann, Thomas Seufferlein, Ingo Gräff et al. (8 authors)

European Journal of Clinical Pharmacology2023-06-293 citations

10.1007/s00228-023-03530-3

Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations

Ingmar Bergs, Katja S. Just, Catharina Scholl, Michael Dreher, Julia Stingl

European Journal of Clinical Pharmacology2022-12-095 citations

10.1007/s00228-022-03433-9

CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System—Results From the ADRED Study

Katja S. Just, Harald Dormann, Mathias Freitag, Marlen Schurig, Miriam Böhme et al. (11 authors)

Frontiers in Pharmacology2021-05-0719 citations

10.3389/fphar.2021.624104

Personalising drug safety-results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED).

Just KS, Dormann H, Böhme M, Schurig M, Schneider KL, Steffens M, Dunow S, Plank-Kiegele B, Ettrich K, Seufferlein T, Gräff I, Igel S, Schricker S, Jaeger SU, Schwab M, Stingl JC.

2019-12-1222 citations

10.1007/s00228-019-02797-9

Interventions

Group 1: Four emergency treatment centers are involved in recruiting patients. In the participating emergency departments during the study period, all patients are reviewed for a causal treatment for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with adverse drug reactions (ADRs), which needed a treatment in an emergency department. In these cases, it comes to enrollment after positive causality assessment of ADRs by the physician. Age =18 years. Capacity to consent and written informed consent of the patient.

Exclusion criteria

Exclusion criteria: Patients treated in the emergency center without UAW by using home medication. (after causality assessment by a health professional in the emergency room). Intentional ingestion of inappropriate drugs or doses, by the patients themselves, which have led to the adverse effect (eg. As with suicidal intent). Age <18 years

Design outcomes

Primary

Measure	Time frame
Primary target is the occurrence of at least one avoidable ADRs (Adverse Drug Reaction) per patient, which have led to hospital emergency treatment. The classification of ADRs as avoidable (medication errors) is being edited with a work of score called Schumock et al. (1992).	—

Secondary

Measure	Time frame
1) Possible causes of preventable ADRs, which have led to hospital emergency treatment: Medication errors types and causes (eg. As dose omission, incorrect application form, wrong patient et cetera.) 2) Possible causes of non-preventable ADRs, which have led to hospital emergency treatment: • Patient-related factors (gender, age, comorbidity et cetera.) • Pharmacogenetic causes of ADRs 3) consequences of ADRs: • Clinical course and severity of the clinical consequences • number of deaths within the observation period • Pharmacoeconomic implications of ADRs / medication errors	—

Measure

Time frame

1) Possible causes of preventable ADRs, which have led to hospital emergency treatment: Medication errors types and causes (eg. As dose omission, incorrect application form, wrong patient et cetera.) 2) Possible causes of non-preventable ADRs, which have led to hospital emergency treatment: • Patient-related factors (gender, age, comorbidity et cetera.) • Pharmacogenetic causes of ADRs 3) consequences of ADRs: • Clinical course and severity of the clinical consequences • number of deaths within the observation period • Pharmacoeconomic implications of ADRs / medication errors

—

Countries

Germany

Contacts

Public ContactMarlen Schurig

Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)Abteilung Forschung

marlen.schurig@bfarm.de0228 99307 3572

Outcome results

None listed